nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Eosinophilia—Auranofin—psoriatic arthritis	0.033	0.033	CcSEcCtD
Oritavancin—Allergic cutaneous angiitis—Methotrexate—psoriatic arthritis	0.0324	0.0324	CcSEcCtD
Oritavancin—Anaemia—Auranofin—psoriatic arthritis	0.0215	0.0215	CcSEcCtD
Oritavancin—Abscess—Prednisolone—psoriatic arthritis	0.0214	0.0214	CcSEcCtD
Oritavancin—Angioedema—Auranofin—psoriatic arthritis	0.0212	0.0212	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Methotrexate—psoriatic arthritis	0.021	0.021	CcSEcCtD
Oritavancin—Abscess—Triamcinolone—psoriatic arthritis	0.0197	0.0197	CcSEcCtD
Oritavancin—Abscess—Methylprednisolone—psoriatic arthritis	0.0197	0.0197	CcSEcCtD
Oritavancin—Abscess—Dexamethasone—psoriatic arthritis	0.0179	0.0179	CcSEcCtD
Oritavancin—Abscess—Betamethasone—psoriatic arthritis	0.0179	0.0179	CcSEcCtD
Oritavancin—Extravasation—Dexamethasone—psoriatic arthritis	0.0162	0.0162	CcSEcCtD
Oritavancin—Extravasation—Betamethasone—psoriatic arthritis	0.0162	0.0162	CcSEcCtD
Oritavancin—Abscess—Prednisone—psoriatic arthritis	0.0156	0.0156	CcSEcCtD
Oritavancin—Wheezing—Triamcinolone—psoriatic arthritis	0.0151	0.0151	CcSEcCtD
Oritavancin—Urticaria—Auranofin—psoriatic arthritis	0.0151	0.0151	CcSEcCtD
Oritavancin—Pruritus—Auranofin—psoriatic arthritis	0.0134	0.0134	CcSEcCtD
Oritavancin—Abscess—Methotrexate—psoriatic arthritis	0.013	0.013	CcSEcCtD
Oritavancin—Diarrhoea—Auranofin—psoriatic arthritis	0.013	0.013	CcSEcCtD
Oritavancin—Vomiting—Auranofin—psoriatic arthritis	0.0121	0.0121	CcSEcCtD
Oritavancin—Rash—Auranofin—psoriatic arthritis	0.012	0.012	CcSEcCtD
Oritavancin—Dermatitis—Auranofin—psoriatic arthritis	0.0119	0.0119	CcSEcCtD
Oritavancin—Extravasation—Methotrexate—psoriatic arthritis	0.0118	0.0118	CcSEcCtD
Oritavancin—Nausea—Auranofin—psoriatic arthritis	0.0113	0.0113	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—psoriatic arthritis	0.0111	0.0111	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—psoriatic arthritis	0.0105	0.0105	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Methylprednisolone—psoriatic arthritis	0.00995	0.00995	CcSEcCtD
Oritavancin—Bronchospasm—Methylprednisolone—psoriatic arthritis	0.0096	0.0096	CcSEcCtD
Oritavancin—Infestation NOS—Methylprednisolone—psoriatic arthritis	0.0087	0.0087	CcSEcCtD
Oritavancin—Infestation—Methylprednisolone—psoriatic arthritis	0.0087	0.0087	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Prednisone—psoriatic arthritis	0.00788	0.00788	CcSEcCtD
Oritavancin—Connective tissue disorder—Methylprednisolone—psoriatic arthritis	0.00767	0.00767	CcSEcCtD
Oritavancin—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00725	0.00725	CcSEcCtD
Oritavancin—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.00705	0.00705	CcSEcCtD
Oritavancin—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00704	0.00704	CcSEcCtD
Oritavancin—Malnutrition—Methylprednisolone—psoriatic arthritis	0.0068	0.0068	CcSEcCtD
Oritavancin—Angioedema—Prednisolone—psoriatic arthritis	0.00677	0.00677	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—psoriatic arthritis	0.00639	0.00639	CcSEcCtD
Oritavancin—Angioedema—Triamcinolone—psoriatic arthritis	0.00622	0.00622	CcSEcCtD
Oritavancin—Angioedema—Methylprednisolone—psoriatic arthritis	0.00621	0.00621	CcSEcCtD
Oritavancin—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00608	0.00608	CcSEcCtD
Oritavancin—Tachycardia—Prednisolone—psoriatic arthritis	0.0059	0.0059	CcSEcCtD
Oritavancin—Myalgia—Triamcinolone—psoriatic arthritis	0.0058	0.0058	CcSEcCtD
Oritavancin—Myalgia—Methylprednisolone—psoriatic arthritis	0.00579	0.00579	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—psoriatic arthritis	0.00576	0.00576	CcSEcCtD
Oritavancin—Infestation—Methotrexate—psoriatic arthritis	0.00576	0.00576	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00575	0.00575	CcSEcCtD
Oritavancin—Angioedema—Dexamethasone—psoriatic arthritis	0.00565	0.00565	CcSEcCtD
Oritavancin—Angioedema—Betamethasone—psoriatic arthritis	0.00565	0.00565	CcSEcCtD
Oritavancin—Immune system disorder—Prednisone—psoriatic arthritis	0.00559	0.00559	CcSEcCtD
Oritavancin—Infection—Triamcinolone—psoriatic arthritis	0.00552	0.00552	CcSEcCtD
Oritavancin—Infection—Methylprednisolone—psoriatic arthritis	0.00551	0.00551	CcSEcCtD
Oritavancin—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00544	0.00544	CcSEcCtD
Oritavancin—Tachycardia—Triamcinolone—psoriatic arthritis	0.00543	0.00543	CcSEcCtD
Oritavancin—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00541	0.00541	CcSEcCtD
Oritavancin—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00539	0.00539	CcSEcCtD
Oritavancin—Malnutrition—Prednisone—psoriatic arthritis	0.00538	0.00538	CcSEcCtD
Oritavancin—Myalgia—Dexamethasone—psoriatic arthritis	0.00526	0.00526	CcSEcCtD
Oritavancin—Myalgia—Betamethasone—psoriatic arthritis	0.00526	0.00526	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00507	0.00507	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00505	0.00505	CcSEcCtD
Oritavancin—Infection—Dexamethasone—psoriatic arthritis	0.00501	0.00501	CcSEcCtD
Oritavancin—Infection—Betamethasone—psoriatic arthritis	0.00501	0.00501	CcSEcCtD
Oritavancin—Anaemia—Prednisone—psoriatic arthritis	0.00498	0.00498	CcSEcCtD
Oritavancin—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00495	0.00495	CcSEcCtD
Oritavancin—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00495	0.00495	CcSEcCtD
Oritavancin—Tachycardia—Dexamethasone—psoriatic arthritis	0.00492	0.00492	CcSEcCtD
Oritavancin—Tachycardia—Betamethasone—psoriatic arthritis	0.00492	0.00492	CcSEcCtD
Oritavancin—Angioedema—Prednisone—psoriatic arthritis	0.00492	0.00492	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—psoriatic arthritis	0.00489	0.00489	CcSEcCtD
Oritavancin—Urticaria—Prednisolone—psoriatic arthritis	0.0048	0.0048	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—psoriatic arthritis	0.0048	0.0048	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—psoriatic arthritis	0.00467	0.00467	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00466	0.00466	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.0046	0.0046	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.0046	0.0046	CcSEcCtD
Oritavancin—Myalgia—Prednisone—psoriatic arthritis	0.00458	0.00458	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00455	0.00455	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—psoriatic arthritis	0.0045	0.0045	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00445	0.00445	CcSEcCtD
Oritavancin—Urticaria—Triamcinolone—psoriatic arthritis	0.00442	0.00442	CcSEcCtD
Oritavancin—Urticaria—Methylprednisolone—psoriatic arthritis	0.00441	0.00441	CcSEcCtD
Oritavancin—Infection—Prednisone—psoriatic arthritis	0.00436	0.00436	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00436	0.00436	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00436	0.00436	CcSEcCtD
Oritavancin—Nervous system disorder—Prednisone—psoriatic arthritis	0.00431	0.00431	CcSEcCtD
Oritavancin—Tachycardia—Prednisone—psoriatic arthritis	0.00429	0.00429	CcSEcCtD
Oritavancin—Skin disorder—Prednisone—psoriatic arthritis	0.00427	0.00427	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—psoriatic arthritis	0.00416	0.00416	CcSEcCtD
Oritavancin—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.0041	0.0041	CcSEcCtD
Oritavancin—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00409	0.00409	CcSEcCtD
Oritavancin—Urticaria—Dexamethasone—psoriatic arthritis	0.00401	0.00401	CcSEcCtD
Oritavancin—Urticaria—Betamethasone—psoriatic arthritis	0.00401	0.00401	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.004	0.004	CcSEcCtD
Oritavancin—Dizziness—Prednisolone—psoriatic arthritis	0.004	0.004	CcSEcCtD
Oritavancin—Pruritus—Triamcinolone—psoriatic arthritis	0.00393	0.00393	CcSEcCtD
Oritavancin—Pruritus—Methylprednisolone—psoriatic arthritis	0.00392	0.00392	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—psoriatic arthritis	0.00383	0.00383	CcSEcCtD
Oritavancin—Rash—Prednisolone—psoriatic arthritis	0.00381	0.00381	CcSEcCtD
Oritavancin—Dermatitis—Prednisolone—psoriatic arthritis	0.00381	0.00381	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.0038	0.0038	CcSEcCtD
Oritavancin—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.0038	0.0038	CcSEcCtD
Oritavancin—Headache—Prednisolone—psoriatic arthritis	0.00379	0.00379	CcSEcCtD
Oritavancin—Dizziness—Triamcinolone—psoriatic arthritis	0.00368	0.00368	CcSEcCtD
Oritavancin—Dizziness—Methylprednisolone—psoriatic arthritis	0.00367	0.00367	CcSEcCtD
Oritavancin—Infection—Methotrexate—psoriatic arthritis	0.00365	0.00365	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—psoriatic arthritis	0.0036	0.0036	CcSEcCtD
Oritavancin—Nausea—Prednisolone—psoriatic arthritis	0.00359	0.00359	CcSEcCtD
Oritavancin—Pruritus—Dexamethasone—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Oritavancin—Pruritus—Betamethasone—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—psoriatic arthritis	0.00357	0.00357	CcSEcCtD
Oritavancin—Vomiting—Triamcinolone—psoriatic arthritis	0.00354	0.00354	CcSEcCtD
Oritavancin—Vomiting—Methylprednisolone—psoriatic arthritis	0.00353	0.00353	CcSEcCtD
Oritavancin—Rash—Triamcinolone—psoriatic arthritis	0.00351	0.00351	CcSEcCtD
Oritavancin—Dermatitis—Triamcinolone—psoriatic arthritis	0.0035	0.0035	CcSEcCtD
Oritavancin—Rash—Methylprednisolone—psoriatic arthritis	0.0035	0.0035	CcSEcCtD
Oritavancin—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00349	0.00349	CcSEcCtD
Oritavancin—Urticaria—Prednisone—psoriatic arthritis	0.00349	0.00349	CcSEcCtD
Oritavancin—Headache—Triamcinolone—psoriatic arthritis	0.00348	0.00348	CcSEcCtD
Oritavancin—Headache—Methylprednisolone—psoriatic arthritis	0.00348	0.00348	CcSEcCtD
Oritavancin—Diarrhoea—Betamethasone—psoriatic arthritis	0.00345	0.00345	CcSEcCtD
Oritavancin—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00345	0.00345	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.00335	0.00335	CcSEcCtD
Oritavancin—Dizziness—Dexamethasone—psoriatic arthritis	0.00334	0.00334	CcSEcCtD
Oritavancin—Dizziness—Betamethasone—psoriatic arthritis	0.00334	0.00334	CcSEcCtD
Oritavancin—Nausea—Triamcinolone—psoriatic arthritis	0.0033	0.0033	CcSEcCtD
Oritavancin—Nausea—Methylprednisolone—psoriatic arthritis	0.0033	0.0033	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisone—psoriatic arthritis	0.00324	0.00324	CcSEcCtD
Oritavancin—Vomiting—Dexamethasone—psoriatic arthritis	0.00321	0.00321	CcSEcCtD
Oritavancin—Vomiting—Betamethasone—psoriatic arthritis	0.00321	0.00321	CcSEcCtD
Oritavancin—Rash—Dexamethasone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Oritavancin—Rash—Betamethasone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Oritavancin—Dermatitis—Betamethasone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Oritavancin—Dermatitis—Dexamethasone—psoriatic arthritis	0.00318	0.00318	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00317	0.00317	CcSEcCtD
Oritavancin—Headache—Betamethasone—psoriatic arthritis	0.00316	0.00316	CcSEcCtD
Oritavancin—Headache—Dexamethasone—psoriatic arthritis	0.00316	0.00316	CcSEcCtD
Oritavancin—Pruritus—Prednisone—psoriatic arthritis	0.00311	0.00311	CcSEcCtD
Oritavancin—Diarrhoea—Prednisone—psoriatic arthritis	0.00301	0.00301	CcSEcCtD
Oritavancin—Nausea—Dexamethasone—psoriatic arthritis	0.003	0.003	CcSEcCtD
Oritavancin—Nausea—Betamethasone—psoriatic arthritis	0.003	0.003	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—psoriatic arthritis	0.00292	0.00292	CcSEcCtD
Oritavancin—Dizziness—Prednisone—psoriatic arthritis	0.00291	0.00291	CcSEcCtD
Oritavancin—Vomiting—Prednisone—psoriatic arthritis	0.00279	0.00279	CcSEcCtD
Oritavancin—Rash—Prednisone—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Oritavancin—Dermatitis—Prednisone—psoriatic arthritis	0.00277	0.00277	CcSEcCtD
Oritavancin—Headache—Prednisone—psoriatic arthritis	0.00275	0.00275	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Oritavancin—Nausea—Prednisone—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—psoriatic arthritis	0.00251	0.00251	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Oritavancin—Rash—Methotrexate—psoriatic arthritis	0.00232	0.00232	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—psoriatic arthritis	0.00231	0.00231	CcSEcCtD
Oritavancin—Headache—Methotrexate—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Oritavancin—Nausea—Methotrexate—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
